Neola Medical (NEOLA) Q1 2026 earnings summary

Executive summary

• Completed enrollment and reported positive safety results from the first clinical pilot study in preterm babies, confirming a favorable safety profile for NeolaⓇ in neonatal intensive care.

• Initiated preparations for the next phase of clinical, regulatory, and commercial development, including a planned U.S. clinical study by mid-2027.

• Board resolved on a SEK 46.8 million rights issue to fund continued development, supported by existing shareholders and management.

Financial highlights

• Operating revenue for Q1 2026 was SEK 2,847k, up from SEK 2,162k in Q1 2025, primarily from capitalized development work.

• Operating result was SEK -3,606k, compared to SEK -2,712k in Q1 2025.

• Cash flow for the period was SEK -6,168k, with cash and cash equivalents at SEK 9,955k at quarter-end.

• Result per share was -0.05 SEK, compared to -0.04 SEK in Q1 2025.

• Equity ratio remained strong at 96%.

Outlook and guidance

• Focus on advancing NeolaⓇ through further preclinical validation, regulatory interactions, and preparation for a U.S. clinical study.

• Planned rights issue expected to provide necessary funding for ongoing development and commercial preparations.